Xenon Pharmaceuticals - Stock Price History | XENE

Historical daily share price chart and data for Xenon Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Xenon Pharmaceuticals as of October 22, 2021 is 30.86.
  • The all-time high Xenon Pharmaceuticals stock closing price was 33.66 on October 15, 2021.
  • The Xenon Pharmaceuticals 52-week high stock price is 34.87, which is 13% above the current share price.
  • The Xenon Pharmaceuticals 52-week low stock price is 9.32, which is 69.8% below the current share price.
  • The average Xenon Pharmaceuticals stock price for the last 52 weeks is 17.34.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Xenon Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 12.5954 13.7200 17.5700 8.0800 15.3800 17.32%
2019 9.5171 6.6800 14.6500 6.3900 13.1100 107.77%
2018 7.6217 2.8750 14.9000 2.7000 6.3100 123.36%
2017 4.3814 7.8500 9.8500 2.2000 2.8250 -63.31%
2016 7.4501 7.9600 8.5500 5.8800 7.7000 -4.23%
2015 12.6255 18.7000 23.0000 7.6900 8.0400 -59.29%
2014 14.6806 10.5000 19.9100 10.5000 19.7500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.269B $0.032B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76